At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 452 enrolled
Drug / intervention
THR-184 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
In Brief
A Phase 2 clinical trial evaluating THR-184 and Placebo for Acute Kidney Injury. Completed, enrolled 452 participants across 41 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether THR-184 when administered around the time of cardiac surgery that requires cardiopulmonary bypass can prevent or ameliorate the development of acute kidney injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Kidney Injury
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionSep 2015
TodayJul 2026
First PostedApr 12, 2013
Enrollment StartMay 1, 2013
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.2 years ago
Interventions
THR-184drug
THR-184 is a synthetic oligopeptide administered intravenously.
Placebodrug
A normal saline solution identical in appearance to the active drug solution